ClinicalTrials.gov record
Active, not recruiting Phase 1Phase 2 Interventional

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

ClinicalTrials.gov ID: NCT05067140

Public ClinicalTrials.gov record NCT05067140. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer

Study identification

NCT ID
NCT05067140
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
152 participants

Conditions and interventions

Interventions

  • ARV-766 + Abiraterone Part C&D Drug
  • ARV-766 Part A&B Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 1, 2021
Primary completion
May 24, 2027
Completion
May 24, 2027
Last update posted
May 4, 2026

2021 – 2027

United States locations

U.S. sites
23
U.S. states
16
U.S. cities
23
Facility City State ZIP Site status
Clinical Trial Site Duarte California 91010
Clinical Trial Site Fresno California 93720
Clinical Trial Site La Jolla California 92037
Clinical Trial Site Orange California 92868
Clinical Trial Site Santa Monica California 90404
Clinical Trial Site New Haven Connecticut 06510
Clinical Trial Site Washington D.C. District of Columbia 20007
Clinical Trial Site Lake Mary Florida 32746
Clinical Trial Site Chicago Illinois 60611
Clinical Trial Site New Orleans Louisiana 70112
Clinical Trial Site Baltimore Maryland 21204
Clinical Trial Site Boston Massachusetts 02114
Clinical Trial Site Detroit Michigan 48201
Clinical Trial Site Buffalo New York 14203
Clinical Trial Site New York New York 10065
Clinical Trial Site Philadelphia Pennsylvania 19144
Clinical Trial Site Pittsburgh Pennsylvania 15232
Clinical Trial Site Myrtle Beach South Carolina 29572
Clinical Trial Site Nashville Tennessee 37203
Clinical Trial Site San Antonio Texas 78229
Clinical Trial Site Charlottesville Virginia 22908
Clinical Trial Site Fairfax Virginia 22031
Clinical Trial Site Madison Wisconsin 53705

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05067140, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 4, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05067140 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →